左甲状腺素治疗对老年亚临床甲减患者肌肉功能、力量与质量的影响
本文为两项随机安慰剂对照试验的辅助研究,纳入267例≥65岁持续性亚临床甲减患者(TSH 4.60–19.99 mIU/l,游离甲状腺素正常),比较每日左甲状腺素(TSH指导调量)与安慰剂模拟滴定。结果显示,左甲状腺素组与安慰剂组在最终访视步速、1年握力和肌肉质量年变化上均无显著差异。
要点
- 老年亚临床甲减患者左甲状腺素治疗未改善步速、握力或肌肉质量。
- 研究纳入TSH 4.60–19.99 mIU/l且游离甲状腺素正常的≥65岁人群。
- 左甲状腺素组最终访视TSH低于安慰剂组,但肌肉结局无差异。
核心结论
- 在两项随机对照试验的辅助分析中,治疗老年亚临床甲减未影响肌肉功能、力量和肌肉质量。
研究设计与样本
- 两项随机安慰剂对照试验的辅助研究,纳入瑞士和荷兰267例≥65岁持续性亚临床甲减患者(TSH 4.60–19.99 mIU/l,游离甲状腺素正常)。
- 干预为每日左甲状腺素加TSH指导剂量调整,对照为安慰剂加模拟滴定;主要结局为最终访视(中位18个月)步速。
主要发现
- 最终访视时左甲状腺素组平均TSH为3.8 mIU/l(SD 2.3),安慰剂组为5.1 mIU/l(SD 1.8,P < 0.05)。
- 最终访视步速组间校正平均差0.01 m/s(95%CI -0.06至0.09)。
- 1年握力组间平均差-1.22 kg(95%CI -2.60至0.15)。
- 肌肉质量年变化组间平均差-0.15 m2(95%CI -0.49至0.18)。
关键数值与推荐
- 入组标准:年龄≥65岁、持续性亚临床甲减、TSH 4.60–19.99 mIU/l、游离甲状腺素正常。
- 主要结局步速在最终访视(中位18个月)评估,次要结局包括1年握力和肌肉质量年变化。
临床怎么用
- 对≥65岁持续性亚临床甲减患者,不应以改善肌肉功能、力量或质量为目的常规启用左甲状腺素。
- 临床决策仍需结合甲减相关症状与TSH水平个体化评估。
局限性
- 本文为两项随机对照试验的辅助研究,原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: loss of skeletal muscle function, strength and mass is common in older adults, with important socioeconomic impacts. Subclinical hypothyroidism is common with increasing age and has been associated with reduced muscle strength. Yet, no randomized placebo-controlled trial (RCT) has investigated whether treatment of subclinical hypothyroidism affects muscle function and mass. METHODS: this is an ancillary study within two RCTs conducted among adults aged ≥65 years with persistent subclinical hypothyroidism (thyrotropin (TSH) 4.60-19.99 mIU/l, normal free thyroxine). Participants received daily levothyroxine with TSH-guided dose adjustment or placebo and mock titration. Primary outcome was gait speed at final visit (median 18 months). Secondary outcomes were handgrip strength at 1-year follow-up and yearly change in muscle mass. RESULTS: we included 267 participants from Switzerland and the Netherlands. Mean age was 77.5 years (range 65.1-97.1), 129 (48.3%) were women, and their mean baseline TSH was 6.36 mIU/l (standard deviation [SD] 1.9). At final visit, mean TSH was 3.8 mIU/l (SD 2.3) in the levothyroxine group and 5.1 mIU/l (SD 1.8, P < 0.05) in the placebo group. Compared to placebo, participants in the levothyroxine group had similar gait speed at final visit (adjusted between-group mean difference [MD] 0.01 m/s, 95% confidence interval [CI] -0.06 to 0.09), similar handgrip strength at one year (MD -1.22 kg, 95% CI -2.60 to 0.15) and similar yearly change in muscle mass (MD -0.15 m2, 95% CI -0.49 to 0.18). CONCLUSIONS: in this ancillary analysis of two RCTs, treatment of subclinical hypothyroidism did not affect muscle function, strength and mass in individuals 65 years and older.
引用
- Netzer S, Chocano-Bedoya P, Feller M, et al. The effect of thyroid hormone therapy on muscle function, strength and mass in older adults with subclinical hypothyroidism-an ancillary study within two randomized placebo controlled trials. Age Ageing. 2023. PMID: 36721961. doi:10.1093/ageing/afac326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。